Abstract
Background/Aims
Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce. We aimed to compare the Helicobacter pylori eradication rates of tegoprazan- and rabeprazole-based triple therapy.
Methods
We retrospectively reviewed data from patients who received first-line treatment for H. pylori infection using tegoprazan- or rabeprazole-based triple therapy for 2 weeks (50 mg tegoprazan or 20 mg rabeprazole+1,000 mg amoxicillin+500 mg clarithromycin twice daily). The primary endpoint was the eradication rate as determined by intention-to-treat analysis.
Results
Of the 677 patients included in our study, 344 and 333 received tegoprazan-based and rabeprazole-based triple therapy, respectively. The eradication rate from intention-to-treat analysis was 76.7% (95% confidence interval [CI], 72.1% to 81.0%) for tegoprazan-based triple therapy and 75.4% (95% CI, 70.5% to 79.8%) for rabeprazole-based triple therapy. There was no significant difference in the eradication rates between the two groups (p>0.999). Per-protocol analysis also revealed no significant difference between the eradication rates of the two groups (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [79.0% to 87.4%], p>0.999). Furthermore, there was no significant difference in adverse event rates between the two groups (tegoprazan, 27.6%; rabeprazole, 25.8%; p=0.604).
Conclusions
The eradication rate of tegoprazan-based triple therapy was similar to that of rabeprazole-based triple therapy. Further studies on the dose-escalation effect of tegoprazan for H. pylori eradication and the efficacy of tegoprazan in regimens other than conventional triple therapy are needed.
Keywords: Helicobacter pylori, Eradication, Potassium-competitive acid blockers, Tegoprazan
INTRODUCTION
Approximately 50% of the global population is infected by Helicobacter pylori,1 that causes various diseases including peptic ulcer disease and gastric cancer.2-6 Recent studies have demonstrated that H. pylori eradication therapy has a beneficial effect on reducing the risk of gastric cancer development.7-9 Active eradication of H. pylori infection has been attempted in East Asian countries,10 where H. pylori and gastric cancer are prevalent. Almost all gastric cancers in East Asia are caused by H. pylori. In Japan, 99.3% of patients with gastric cancer had current or past H. pylori infection, whereas the prevalence of H. pylori-negative gastric cancer was only 0.7%.11 In Japan and Korea, health insurance coverage has been expanded to include individuals with H. pylori infection.12
Approximately 30 years ago, as proton pump inhibitors (PPIs) became available, they began to be used for H. pylori eradication.13 PPI-containing eradication regimens have superior efficacy compared to other regimens that do not employ PPIs.14 Since 1993, PPI-based triple therapy, consisting of PPIs, amoxicillin, and clarithromycin, has been widely used worldwide.15-17 Recently, potassium-competitive acid blockers (P-CABs) have been used as alternative drugs for gastric acid inhibition. Because P-CABs have a faster onset and longer lasting acid-inhibitory effect compared with PPIs,18 the P-CAB-based regimen is expected to be superior to PPI-based regimens in terms of efficacy. In a previous meta-analysis, a triple therapy regimen containing vonoprazan, a P-CAB approved in 2014 in Japan, demonstrated a 1.2 times better eradication rate than the PPI-based triple therapy regimen.19 However, all individual studies in the meta-analysis were performed in Japan and did not evaluate the efficacy of P-CABs other than vonoprazan.19
In 2018, tegoprazan, a novel P-CAB with fast onset of action and strong acid-inhibitory potency, was approved for gastroesophageal reflux disease in Korea.20 A multicenter, randomized controlled, noninferior study on erosive esophagitis showed that tegoprazan was noninferior to esomeprazole with regards to healing of esophageal erosion.21 In addition, tegoprazan was shown to be superior to placebo in terms of symptom resolution in patients with non-erosive reflux disease.22 In 2020, tegoprazan was approved for H. pylori eradication therapy and is now widely available in Korea. However, there is little evidence of the clinical efficacy of tegoprazan-based triple therapy for H. pylori eradication. Therefore, this study aimed to evaluate the efficacy and tolerability of tegoprazan-based triple therapy by comparing it with rabeprazole-based triple therapy, based on real-world data.
MATERIALS AND METHODS
1. Study population
We retrospectively reviewed the data of consecutive adult patients (≥19 years of age) with H. pylori infection who received tegoprazan-based or rabeprazole-based triple therapy between March and July 2021 at Kangbuk Samsung Hospital and Hanyang University Guri Hospital in Korea. The exclusion criteria were as follows: (1) previous history of H. pylori eradication therapy and (2) previous history of subtotal gastrectomy. Patient demographics, symptoms, upper endoscopic findings, medications, H. pylori eradication therapy-related adverse events, and results of H. pylori eradication therapy were obtained. The institutional review boards of each institution approved this study (IRB numbers: Kangbuk Samsung Hospital [KBSMC 2021-08-021] and Hanyang University Guri Hospital [GURI 2021-09-004]). The informed consent was waived.
2. H. pylori eradication therapy
First-line treatment of H. pylori infection involved the administration of an acid suppressant (either 50 mg tegoprazan or 20 mg rabeprazole) in combination with 1,000 mg amoxicillin and 500 mg clarithromycin twice daily for 2 weeks according to the current Korean guidelines.23 The Ministry of Food and Drug Safety of Korea approved both PPIs and tegoprazan for H. pylori eradication therapy. There were no clinical practice guidelines for the selection of acid suppressants. In our institutes, acid suppressant for H. pylori eradication therapy was selected at the clinicians’ discretion. Because the antibiotics susceptibility test was unavailable in our clinical setting, either PPI or tegoprazan was selected regardless of antibiotics resistance status. Eradication status was usually evaluated at least 4 weeks after treatment. If eradication of H. pylori infection had failed, second-line H. pylori eradication therapy was initiated with an acid suppressant (one of 50 mg tegoprazan, 20 mg rabeprazole, or 40 mg esomeprazole) twice daily in combination with 120 mg bismuth four times a day, 500 mg metronidazole three times a day, and 500 mg tetracycline four times a day for 2 weeks. Eradication status following second-line therapy was also evaluated at least 4 weeks after treatment.
3. Study endpoint and measurements
The primary study endpoint was H. pylori eradication rate with first-line treatment in the intention-to-treat (ITT) analysis. The secondary study endpoints were H. pylori eradication rate with first-line therapy in the per-protocol (PP) analysis, H. pylori eradication rate with second-line treatment in the ITT and PP analyses, and adverse events of H. pylori eradication therapy.
The presence of H. pylori was detected using one or more of the following tests: rapid urease test, 13C-urea breath test (Korea Otsuka Pharmaceutical Co., Ltd., Seoul, Korea), and/or histologic evaluation with modified Giemsa staining. H. pylori infection was defined as a positive result obtained using any of the above three tests.
Indications for H. pylori eradication were classified based on endoscopic findings according to the current guidelines for the management of H. pylori infections.23 The severity of atrophic gastritis was determined visually based on the Kimura-Takemoto classification,24 which classifies atrophic gastritis into three categories as follows: mild (C-1, C-2), moderate (C-3, O-1), and severe (O-2, O-3). Additionally, drug adherence was determined by the administration of ≥80% of prescribed medications.
4. Statistical analysis
Continuous and categorical variables were compared using the t-test and Fisher exact test, respectively. H. pylori eradication rate was primarily evaluated in the ITT population. All enrolled patients were included in the ITT analysis, and those who received insufficient medications (<80% of the prescribed medications) or were lost to follow-up were regarded as failing to be cured. PP analysis was performed after excluding patients with insufficient medications and those lost to follow-up. Logistic regression analysis was used to identify factors associated with the failure of first-line H. pylori eradication therapy. Age, sex, and variables with p-values <0.1 in the univariable logistic regression model were considered as covariates for the multivariable analysis.
All reported p-values were two-sided and statistical significance was set at p<0.05. All statistical analyses were conducted using R statistical software version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
1. Study population and baseline characteristics
During the study period, 1,264 patients received H. pylori eradication therapy. Of them, 708 patients who underwent 14-day tegoprazan- or rabeprazole-based triple therapy for H. pylori infection were eligible for inclusion in this study (Fig. 1). Of these, 30 patients were excluded due to a history of H. pylori eradication therapy. One patient with a history of subtotal gastrectomy was excluded from this study. Consequently, a total of 677 patients were included in the analyses. For ITT analysis, 344 patients in the tegoprazan-based triple therapy group and 333 in the rabeprazole-based triple therapy group were included. After excluding 65 patients due to insufficient medication or loss to follow-up, 313 patients in the tegoprazan-based triple therapy group and 297 patients in the rabeprazole-based triple therapy group were included in the PP analysis. Second-line H. pylori eradication therapy was administered to 67 patients for whom first-line eradication therapy failed.
Fig. 1.
Study flow diagram. PBMT indicates Helicobacter pylori eradication regimens consisting of proton pump inhibitor (or P-CAB), bismuth, metronidazole, and tetracycline.
ITT, intention-to-treat; PP, per protocol; P-CAB, potassium-competitive acid blocker. *Insufficient medication is determined as administration of <80% of prescribed medications.
Baseline patient characteristics are shown in Table 1. The mean age was 56.2±11.4 years in the tegoprazan-based triple therapy group and 57.4±11.6 years in the rabeprazole-based triple therapy group (p=0.147). The proportion of male sex was 54.9% in the tegoprazan-based triple therapy group and 54.4% in the rabeprazole-based triple therapy group (p=0.938). Body mass index, smoking habits, alcohol use, comorbidity, and the use of antithrombotic agents did not differ between the tegoprazan- and rabeprazole-based triple therapy groups.
Table 1.
Baseline Patient Characteristics
| Variable | Tegoprazan-based triple therapy (n=344) |
Rabeprazole-based triple therapy (n=333) |
p-value |
|---|---|---|---|
| Age, yr | 56.2±11.4 | 57.4±11.6 | 0.147 |
| Male sex | 189 (54.9) | 181 (54.4) | 0.938 |
| Body mass index, kg/m2* | 24.2±3.1 | 23.9±3.3 | 0.380 |
| Smoking habit | 0.623 | ||
| Never smoker | 196 (57.0) | 199 (59.8) | |
| Former smoker | 94 (27.3) | 80 (24.0) | |
| Current smoker | 54 (15.7) | 54 (16.2) | |
| Alcohol use | 0.818 | ||
| Absent | 177 (51.5) | 168 (50.5) | |
| Present | 167 (48.5) | 165 (49.5) | |
| <2/wk | 102 (29.7) | 82 (24.6) | |
| ≥2/wk | 65 (18.9) | 83 (24.9) | |
| Comorbidity | |||
| Hypertension | 81 (23.5) | 88 (26.4) | 0.424 |
| Cardiovascular disease | 11 (3.2) | 6 (1.8) | 0.327 |
| Diabetes | 35 (10.2) | 28 (8.4) | 0.509 |
| Cerebrovascular accident | 11 (3.2) | 10 (3.0) | >0.999 |
| Antithrombotic agent | |||
| Any antithrombotic agent | 26 (7.6) | 28 (8.4) | 0.777 |
| Aspirin | 15 (4.4) | 15 (4.5) | >0.999 |
| Clopidogrel | 8 (2.3) | 10 (3.0) | 0.639 |
| Other antiplatelet agent | 5 (1.5) | 1 (0.3) | 0.217 |
| Warfarin | 0 | 2 (0.6) | 0.242 |
| Non-vitamin K-dependent oral anticoagulant | 2 (0.6) | 0 | 0.499 |
| Others (types unknown) | 0 | 2 (0.6) | 0.242 |
Data are presented as mean±SD or number (%).
*Body mass index is missing in one patient from the tegoprazan-based triple therapy group.
Baseline patient symptoms and endoscopic findings are shown in Table 2. Although abdominal discomfort was more common in the tegoprazan-based triple therapy group (13.4%) than in the rabeprazole-based triple therapy group (8.1%), other symptoms, including reflux, nausea or vomiting, gastric soreness, and abdominal pain did not differ between the groups. The most common indication for H. pylori eradication was H. pylori-associated gastritis, followed by gastric or duodenal ulcers, in both the tegoprazan- and rabeprazole-based triple therapy groups. Atrophic gastritis was present in 79.6% and 84.4% of the tegoprazan-based and rabeprazole-based triple therapy groups, respectively (p=0.410).
Table 2.
Baseline Symptoms and Endoscopic Findings
| Variable | Tegoprazan-based triple therapy (n=344) | Rabeprazole-based triple therapy (n=333) | p-value |
|---|---|---|---|
| Symptom | |||
| Reflux symptom* | 9 (2.6) | 10 (3.0) | 0.819 |
| Nausea or vomiting | 5 (1.5) | 4 (1.2) | >0.999 |
| Gastric soreness | 30 (8.7) | 32 (9.6) | 0.692 |
| Abdominal discomfort | 46 (13.4) | 27 (8.1) | 0.035 |
| Abdominal pain | 10 (2.9) | 7 (2.1) | 0.625 |
| Others† | 7 (2.0) | 6 (1.8) | >0.999 |
| Indication for H. pylori eradication | 0.182 | ||
| Gastric and duodenal ulcers | 0 | 1 (0.3) | |
| Gastric ulcer | 27 (7.8) | 17 (5.1) | |
| Duodenal ulcer | 27 (7.8) | 33 (9.9) | |
| EGC treated with ESD | 5 (1.5) | 1 (0.3) | |
| Gastric adenoma treated with ESD | 3 (0.9) | 1 (0.3) | |
| H. pylori-associated gastritis | 282 (82.0) | 280 (84.1) | |
| Nodular gastritis | 18 (5.2) | 11 (3.3) | 0.256 |
| Atrophic gastritis‡,§ | 0.410 | ||
| Absent (C-0) | 70 (20.4) | 52 (15.6) | |
| Present | |||
| C-1 | 79 (23.0) | 90 (27.0) | |
| C-2 | 48 (14.0) | 44 (13.2) | |
| C-3 | 56 (16.3) | 70 (21.0) | |
| O-1 | 30 (8.7) | 25 (7.5) | |
| O-2 | 39 (11.4) | 32 (9.6) | |
| O-3 | 21 (6.1) | 20 (6.0) | |
Data are presented as number (%).
H. pylori, Helicobacter pylori; EGC, early gastric cancer; ESD, endoscopic submucosal dissection.
*Reflux symptoms include heartburn and acid regurgitation; †Other symptoms include anorexia, globus sensation, belching, and diarrhea; ‡Severity of atrophic gastritis is determined by Kimura-Takemoto classification;24 §There is one missing value for atrophic gastritis in the tegoprazan-based triple therapy group.
2. Efficacy of the first-line eradication therapy
The success rate of first-line H. pylori eradication therapy is shown in Fig. 2. In the ITT analysis, there was no significant difference between the tegoprazan- and rabeprazole-based triple therapy groups (tegoprazan 76.7% [95% confidence interval (CI), 72.1% to 81.0%] vs rabeprazole 75.4% [95% CI, 70.5% to 79.8%], p>0.999). Likewise, there was no significant difference between the two groups in the PP analysis (tegoprazan 83.4% [95% CI, 79.0% to 87.2%] vs rabeprazole 83.5% [95% CI, 79.0% to 87.4%], p>0.999). As shown in Table 3, the most common confirmation test after H. pylori eradication was the urea breath test (96.2% in the tegoprazan group and 99.7% in the rabeprazole group). Although the type of confirmation test and lag period for confirmation test after H. pylori eradication therapy slightly differed between the groups, the eradication rate did not differ according to the type of confirmation test (p=0.139) and lag period (p=0.664).
Fig. 2.
Success rate of first-line Helicobacter pylori eradication therapy.
ITT, intention-to-treat; PP, per-protocol.
Table 3.
Adherence and Adverse Events of First-Line Helicobacter pylori Eradication Therapy
| Variable | Tegoprazan-based triple therapy (n=344) |
Rabeprazole-based triple therapy (n=333) |
p-value |
|---|---|---|---|
| Adherence* | 313 (91.0) | 297 (89.2) | 0.443 |
| Non-adjherence | 31 (9.0) | 36 (10.8) | |
| Loss of follow-up | 24 (7.0) | 34 (10.2) | |
| Insufficient medication | 7 (2.0) | 2 (0.6) | |
| Adverse event† | |||
| Any adverse event | 95 (27.6) | 86 (25.8) | 0.604 |
| General weakness | 1 (0.3) | 0 | >0.999 |
| Dizziness | 0 | 0 | NA |
| Headache | 3 (0.9) | 2 (0.6) | >0.999 |
| Myalgia | 0 | 0 | NA |
| Acid regurgitation | 0 | 0 (0.1) | 0.492 |
| Nausea or vomiting | 16 (4.7) | 14 (4.2) | 0.853 |
| Dysgeusia | 43 (12.5) | 33 (9.9) | 0.330 |
| Abdominal discomfort | 8 (2.3) | 10 (3.0) | 0.639 |
| Abdominal pain | 2 (0.6) | 1 (0.3) | >0.999 |
| Diarrhea | 27 (7.8) | 40 (12.0) | 0.073 |
| Constipation | 3 (0.9) | 0 | 0.249 |
| Skin rash | 5 (1.5) | 2 (0.6) | 0.451 |
| Others‡ | 4 (1.2) | 1 (0.3) | 0.373 |
| Confirmation test for H. pylori eradication | 0.003 | ||
| Urea breath test | 307 (96.2) | 302 (99.7) | |
| Histologic evaluation with modified Giemsa staining | 12 (3.8) | 1 (0.3) | |
| Lag period for confirmation test after eradication therapy | 0.016 | ||
| <2 wk | 1 (0.3) | 0 | |
| 2–4 wk | 10 (3.1) | 10 (3.3) | |
| 4–12 wk | 307 (96.2) | 283 (93.4) | |
| 12–24 wk | 1 (0.3) | 10 (3.3) | |
Data are presented as number (%).
NA, not applicable.
*Adherence is determined as administration of ≥80% of prescribed medications; †Percentage is calculated based on the intention-to-treat population; ‡Other adverse events include sores on the tongue, dry mouth, palpitation, anal bleeding, and insomnia.
Here, we further performed the eradication rate according to the clinicians because acid suppressant for H. pylori eradication therapy was selected at the clinicians’ discretion in this study. As shown in Supplementary Table 1, the eradication rate did not differ among the participated clinicians (p=0.160).
In total, there were 67 patients who received second-line H. pylori eradication therapy due to failure of first-line eradication therapy. Of the 41 patients with failed eradication in the tegoprazan-based triple therapy group, 40 received tegoprazan-based second-line therapy and one received rabeprazole-based second-line therapy. Of the 26 patients with failed eradication in the rabeprazole-based triple therapy group, 16 received rabeprazole-based second-line therapy, nine received esomeprazole-based second-line therapy, and one received tegoprazan-based second-line therapy. Following second-line H. pylori eradication therapy, the eradication rate of tegoprazan-based therapy did not differ from that of rabeprazole- or esomeprazole-based therapy in both the ITT and PP analyses (ITT analysis: tegoprazan 85.4% [95% CI, 72.3% to 93.7%] vs rabeprazole 82.4% [95% CI, 60.0% to 94.8%], p>0.999 and vs esomeprazole 88.9% [95% CI, 58.6% to 98.8%], p>0.999; PP analysis: tegoprazan 94.6% [95% CI, 83.8% to 98.9%] vs rabeprazole 100.0% [95% CI, 83.8% to 100.0%], p>0.999 and vs esomeprazole 100.0% [95% CI, 70.8% to 100.0%], p>0.999) (Supplementary Fig. 1).
3. Adherence and adverse events
The adherence rate to first-line eradication therapy was 91.0% in the tegoprazan-based triple therapy group and 89.2% in the rabeprazole-based triple therapy group (p=0.443) (Table 3). The most common adverse events were dysgeusia (12.5%) and diarrhea (12.0%) in the tegoprazan-based and rabeprazole-based triple therapy groups, respectively. The proportion of patients who experienced adverse events was 27.6% in the tegoprazan-based triple therapy group and 25.8% in the rabeprazole-based triple therapy group (p=0.604). Furthermore, no adverse event was significantly different between the patients in the two groups.
The adherence rates to second-line eradication therapy were 90.2%, 82.4%, and 77.8% in the tegoprazan-, rabeprazole-, and esomeprazole-based second-line therapy groups, respectively, and there was no significant difference in adherence between groups (p=0.390) (Supplementary Table 2). The most common adverse event was nausea or vomiting in the tegoprazan-based (24.4%) and esomeprazole-based (22.2%) second-line therapy groups. In the rabeprazole-based second-line therapy group, abdominal discomfort (11.8%) and diarrhea (11.8%) were the most common adverse events. There were no significant differences in adverse events between the groups.
4. Risk factor for H. pylori eradication failure
Table 4 shows the factors associated with the failure of first-line H. pylori eradication therapy. In the univariable analysis, non-adherence, female sex, former or current smoker, alcohol use ≥2/week, and diabetes were associated with failed eradication. In the multivariable analysis, diabetes (odds ratio, 2.03; 95% CI, 1.05 to 3.95) was significantly associated with eradication failure. The choice of acid suppressant did not affect eradication failure (tegoprazan vs rabeprazole: odds ratio, 1.02; 95% CI, 0.66 to 1.57).
Table 4.
Factors Associated with Failure of First-Line Helicobacter pylori Eradication*
| Variable | No. | Failure, No. (%) |
Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||||
| Regimen | |||||||
| Tegoprazan-based triple therapy | 316 | 54 (17.1) | 1.03 (0.67–1.57) | 0.904 | 1.03 (0.67–1.59) | 0.888 | |
| Rabeprazole-based triple therapy | 299 | 50 (16.7) | 1 | 1 | |||
| Adherence | |||||||
| Adherent | 611 | 101 (16.5) | 1 | 1 | |||
| Non-adherent | 4 | 3 (75.0) | 5.03 (1.01–25.28) | 0.050 | 4.05 (0.78–21.04) | 0.097 | |
| Age | |||||||
| <60 yr | 339 | 55 (16.2) | 1 | 1 | |||
| ≥60 yr | 276 | 49 (17.8) | 1.12 (0.73–1.70) | 0.615 | 0.98 (0.62–1.55) | 0.928 | |
| Sex | |||||||
| Male | 338 | 42 (12.4) | 1 | 1 | |||
| Female | 277 | 62 (22.4) | 2.03 (1.32–3.12) | 0.001 | 1.49 (0.84–2.64) | 0.169 | |
| Body mass index | |||||||
| <25 kg/m2 | 378 | 65 (17.2) | 1 | ||||
| ≥25 kg/m2 | 237 | 39 (16.5) | 0.95 (0.61–1.47) | 0.948 | |||
| Smoking habit | |||||||
| Never smoker | 358 | 75 (20.9) | 1 | 1 | |||
| Former smoker | 165 | 20 (12.1) | 0.52 (0.31–0.89) | 0.016 | 0.65 (0.33–1.27) | 0.206 | |
| Current smoker | 92 | 9 (9.8) | 0.41 (0.20–0.85) | 0.017 | 0.54 (0.23–1.25) | 0.147 | |
| Alcohol use | |||||||
| Absent | 309 | 61 (19.7) | 1 | 1 | |||
| <2/wk | 173 | 28 (16.2) | 0.79 (0.48–1.28) | 0.335 | 1.08 (0.63–1.85) | 0.778 | |
| ≥2/wk | 133 | 15 (11.3) | 0.52 (0.28–0.95) | 0.033 | 0.92 (0.45–1.86) | 0.816 | |
| Comorbidity | |||||||
| Hypertension | 155 | 32 (20.6) | 1.40 (0.88–2.23) | 0.153 | |||
| Cardiovascular disease | 17 | 5 (29.4) | 2.10 (0.72–6.09) | 0.172 | |||
| Diabetes | 57 | 15 (26.3) | 1.88 (1.00–3.54) | 0.050 | 2.03 (1.05–3.95) | 0.036 | |
| Cerebrovascular accident | 20 | 1 (5.0) | 0.25 (0.03–1.90) | 0.181 | |||
| Antithrombotic agent | 48 | 12 (25.0) | 1.72 (0.86–3.43) | 0.123 | |||
| Symptom | |||||||
| Reflux symptom† | 18 | 0 | NA | 0.998 | |||
| Nausea or vomiting | 9 | 1 (11.1) | 0.61 (0.08–4.93) | 0.643 | |||
| Gastric soreness | 53 | 8 (15.1) | 0.86 (0.39–1.90) | 0.712 | |||
| Abdominal discomfort | 68 | 15 (22.1) | 1.46 (0.79–2.70) | 0.232 | |||
| Abdominal pain | 16 | 2 (12.5) | 0.70 (0.16–3.11) | 0.635 | |||
| Others‡ | 11 | 2 (18.2) | 1.09 (0.23–5.14) | 0.910 | |||
| Indication for H. pylori eradication | |||||||
| Peptic ulcer | 92 | 16 (17.4) | 1.08 (0.60–1.94) | 0.809 | |||
| EGC treated with ESD | 6 | 3 (50.0) | 5.11 (1.01–25.74) | 0.048 | |||
| Gastric adenoma treated with ESD | 4 | 1 (25.0) | 1.70 (0.18–16.56) | 0.647 | |||
| H. pylori-associated gastritis | 513 | 84 (16.4) | 1 | ||||
| Nodular gastritis | 28 | 4 (14.3) | 0.81 (0.28–2.39) | 0.705 | |||
| Atrophic gastritis§ | |||||||
| Normal (C-0) | 110 | 17 (15.5) | 1 | ||||
| Mild (C-1, C-2) | 236 | 36 (15.3) | 0.99 (0.53–1.84) | 0.962 | |||
| Moderate (C-3, O-1) | 168 | 32 (19.0) | 1.29 (0.68–2.45) | 0.443 | |||
| Severe (O-2, O-3) | 101 | 19 (18.8) | 1.27 (0.62–2.60) | 0.518 | |||
OR, odds ratio; CI, confidence interval; EGC, early gastric cancer; ESD, endoscopic submucosal dissection; NA, not applicable.
*This analysis is performed on participants who received a follow-up test for H. pylori eradication; †Reflux symptoms include heartburn and acid regurgitation; ‡Other symptoms include anorexia, globus sensation, belching, and diarrhea; §Severity of atrophic gastritis is determined by Kimura-Takemoto classification.24
DISCUSSION
In this study, the H. pylori eradication rate of tegoprazan-based triple therapy was 76.7% in the ITT analysis and 83.4% in the PP analysis. Similarly, the eradication rate of rabeprazole-based triple therapy was 75.4% in the ITT analysis and 83.5% in the PP analysis. Our findings demonstrate that the choice of acid suppressant between tegoprazan and rabeprazole did not affect the eradication rate of first-line triple therapy lasting 2 weeks. Although tegoprazan showed a fast and strong acid inhibitory effect,20 it did not increase the eradication rate of conventional triple therapy in our real-world data. Tegoprazan-based triple therapy demonstrated a good adherence rate (91.3%) and acceptable adverse events. However, given that acceptable regimens typically require a >85% eradication rate in ITT analysis and >90% eradication rate in PP analysis,25 tegoprazan-based triple therapy did not achieve an acceptable eradication rate in either the ITT (76.7%) or PP (83.4%) analyses.
Owing to the strong acid-inhibitory potency of vonoprazan, vonoprazan-based triple therapy has been reported to increase the eradication rate.26 Even in patients with clarithromycin-resistant H. pylori infection, the eradication rate of vonoprazan-based triple therapy is over 80%.26 Effective acid suppression improves antibiotic potency by minimizing antibiotic degradation, maximizing the concentration of antibiotics in gastric juice, and increasing the susceptibility of H. pylori to antibiotics.27 In a previous study, patients with H. pylori infection with strong acid inhibition (intragastric pH >6.5) were successfully treated with triple therapy despite clarithromycin resistance, whereas patients with modest acid inhibition (intragastric pH=6) who were infected with clarithromycin-resistant strains failed to respond to triple therapy.28 These studies suggest that strong acid inhibition is helpful in increasing the eradication rate of H. pylori eradication therapy.
In contrast to the superior efficacy of vonoprazan in the treatment of H. pylori infection,19 our study did not demonstrate superior efficacy of tegoprazan compared to PPIs; this may be due to an insufficient dosage of tegoprazan (50 mg, twice daily). For vonoprazan-based eradication therapy, the dosage of vonoprazan (20 mg, twice a day) is four-times higher than the maintenance dosage for reflux esophagitis (10 mg, once a day).29 In Korea, 50 mg tegoprazan taken once daily has been approved for gastroesophageal reflux disease, including both erosive esophagitis and non-erosive reflux disease; however, only a 2-fold higher dosage (50 mg, twice daily) has been approved for H. pylori eradication therapy. A previous study demonstrated that tegoprazan inhibits proton pumps in a dose-dependent manner.20 When the dosage of tegoprazan was increased from 100 mg once daily to 200 mg once daily, the median intragastric pH increased from 5.2 to 6.4.20 In treating H. pylori infection, 100 mg tegoprazan taken twice daily may be more effective.
To date, two studies have compared the effects of tegoprazan and PPIs in H. pylori eradication.30,31 One retrospective study by Kim et al.,30 published in 2021, assessed the comparative efficacy of bismuth-containing quadruple regimens consisting of 50 mg tegoprazan, 30 mg lansoprazole, 1,000 mg amoxicillin, 500 mg clarithromycin, and 300 mg bismuth potassium citrate administered twice daily for 7 days. Consistent with our findings, this study did not demonstrate superior efficacy of tegoprazan-based therapy compared with PPI-based therapy. In the ITT analysis, the eradication rates in the tegoprazan and lansoprazole groups were 78.8% (152/193) and 74.5% (140/188), respectively (p=0.323). In the PP analysis, the eradication rates of the two groups were 88.3% (151/171) and 82.8% (140/169), respectively (p=0.151). Although the eradication regimens and treatment durations differed between the study by Kim et al.30 and our study, the eradication rates were similar between tegoprazan-based and rabeprazole-based therapies in both studies. Additionally, in the study by Kim et al.,30 clarithromycin resistance gene mutation analysis showed that the eradication rate of tegoprazan-based therapy was lower than 20%. However, a limitation of this study is that H. pylori eradication therapy was administered for only 1 week. Currently, Korean guidelines recommend several empirical eradication regimens, including conventional triple therapy for 2 weeks if an antibiotic susceptibility test is not performed.23 In our study, we administered H. pylori eradication therapy for 2 weeks in accordance with these guidelines.23 One recently published randomized controlled trial also evaluated the efficacy of 7-day tegoprazan-based triple therapy in the treatment of H. pylori infection.31 In this study, the efficacy of 7-day tegoprazan-based triple therapy was similar to that of 7-day lansoprazole-based triple therapy. The H. pylori eradication rate in the ITT analysis was 62.9% in the tegoprazan group and 60.6% in the lansoprazole group. Comparing the results from the randomized controlled trial with our study findings, 50 mg of tegoprazan may have similar efficacy in terms of H. pylori eradication compared to the standard dose of PPI.
In our study, nonadherence to medication was associated with eradication failure. Although both tegoprazan- and rabeprazole-based triple therapies showed acceptable adherence rates, insufficient medication (<80% of prescribed medications) may increase the risk of eradication failure; thus, it is essential to educate patients about the risks of nonadherence. Diabetes is a significant risk factor for eradication failure; patients with diabetes had a 2-fold higher risk of eradication failure than those without. This finding is consistent with previous studies. In a meta-analysis of eight studies comparing eradication rates between patients with and without diabetes, the pooled risk ratio of H. pylori eradication failure was 2.19.32 Several potential mechanisms may contribute to the poor eradication rate in patients with diabetes.32 First, glycosylation reduces drug binding in the blood.33 Second, the impaired microvasculature of the gastric mucosa in patients with diabetes may reduce antibiotic absorption.34 Third, diabetic gastroparesis may result in reduced antibiotic absorption.35,36 And fourth, antibiotic resistance may be common in patients with diabetes because of the frequent use of antibiotics.37
Although our study is the first comparative study of tegoprazan- versus PPI-based triple therapy for H. pylori eradication, it has several limitations. First, as a retrospective study, there may have been selection bias as the treatment groups were not allocated randomly, but rather were selected according to the clinicians’ preference. However, the potential bias arising from clinicians may be minimal as the treatment process for H. pylori infection, including diagnosis, prescription tools, medication preparation, and follow-up tests, is similar across clinicians in our institutes. Second, we did not perform antibiotic susceptibility tests. Also, the frequency of previous antibiotic use was not identified. Therefore, the efficacy of tegoprazan-based therapy in patients with clarithromycin-resistant H. pylori infections could not be assessed. However, bias due to a lack of antibiotics susceptibility tests may be minimal because H. pylori eradication regimens were chosen according to the clinicians’ preference without knowing the antibiotics susceptibility status. According to current guidelines, conventional triple therapy is not recommended if clarithromycin-resistant H. pylori infection is confirmed.23 In other words, most real-world patients confirmed to be infected with clarithromycin-resistant H. pylori are treated with eradication regimens other than conventional triple therapy. Therefore, our real-world study on tegoprazan-based triple therapy could only be conducted in an empirical treatment setting. Third, cytochrome P450 2C19 (CYP2C19) status was unavailable in this study. The eradication rate of PPI-based triple therapy may differ depending on CYP2C19 status since most PPIs are metabolized by CYP2C19.38 However, rabeprazole is mainly metabolized via nonenzymatic pathway, rather than CYP2C19.38 Additionally, tegoprazan is metabolized by cytochrome P450 3A4, and not CYP2C19. The eradication efficacy of rabeprazole- or tegoprazan-based triple therapy likely does not differ between patients with different CYP2C19 genetic polymorphisms.39 Fourth, we investigated atrophic gastritis status based on gross endoscopic findings. Therefore, atrophic gastritis may not be fully evaluated in some patients with endoscopic findings associated with current H. pylori infection, including hemorrhagic spots, diffuse redness, mucosal edema, and thick and sticky mucus. If atrophic gastritis was assessed by histologic examination, the proportion of atrophic gastritis may have increased. Lastly, our study included only patients who received triple therapy consisting of an acid suppressant, amoxicillin, and clarithromycin. Accordingly, the effect of tegoprazan in combination with other antibiotic regimens, including concomitant therapy, could not be evaluated. As both the 2-week tegoprazan- and 2-week rabeprazole-based triple therapies did not achieve acceptable eradication rates, the clinical efficacy of tegoprazan should be investigated in more effective H. pylori eradication regimens.
Our study enhances the understanding of the clinical efficacy of tegoprazan-based triple therapy for the treatment of H. pylori infection. Although tegoprazan-based triple therapy demonstrated good adherence and acceptable adverse events, its eradication rate was similar to that of rabeprazole-based triple therapy. Future studies are warranted to evaluate the dose-escalation effect of tegoprazan in the treatment of H. pylori infection and the efficacy of tegoprazan in regimens other than conventional triple therapy.
SUPPLEMENTARY MATERIALS
Supplementary materials can be accessed at https://doi.org/10.5009/gnl220218.
ACKNOWLEDGEMENTS
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP; Ministry of Science, ICT & Future Planning) (No. NRF-2021R1C1C1005728).
Footnotes
CONFLICTS OF INTEREST
Y.S.J. is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
AUTHOR CONTRIBUTIONS
Study concept and design: C.H.P. Data acquisition: Y.S.J., C.H.P. Data analysis and interpretation: Y.S.J., C.H.P. Drafting of the manuscript; critical revision of the manuscript for important intellectual content: Y.S.J., S.K., H.Y.K., S.J.N., J.H.P., C.I.S., C.H.P. Statistical analysis: Y.S.J., C.H.P. Obtained funding: C.H.P. Administrative, technical, or material support; study supervision: C.H.P. Approval of final manuscript: all authors.
REFERENCES
- 1.Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries: World Gastroenterology Organisation global guideline. J Gastrointestin Liver Dis. 2011;20:299–304. [PubMed] [Google Scholar]
- 2.McColl KE. Clinical practice: Helicobacter pylori infection. N Engl J Med. 2010;362:1597–1604. doi: 10.1056/NEJMcp1001110. [DOI] [PubMed] [Google Scholar]
- 3.de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–615. doi: 10.1016/S1470-2045(12)70137-7. [DOI] [PubMed] [Google Scholar]
- 4.Guerra-Valle M, Orellana-Palma P, Petzold G. Plant-based polyphenols: anti-Helicobacter pylori effect and improvement of gut microbiota. Antioxidants (Basel) 2022;11:109. doi: 10.3390/antiox11010109.c0c038fb99cb454981afb697cd93b32b [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53:33–50. doi: 10.1007/s42770-021-00675-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Araújo GR, Marques HS, Santos ML, et al. Helicobacter pylori infection: how does age influence the inflammatory pattern? World J Gastroenterol. 2022;28:402–411. doi: 10.3748/wjg.v28.i4.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ. 2019;366:l5016. doi: 10.1136/bmj.l5016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382:427–436. doi: 10.1056/NEJMoa1909666. [DOI] [PubMed] [Google Scholar]
- 9.Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69:2113–2121. doi: 10.1136/gutjnl-2020-320839. [DOI] [PubMed] [Google Scholar]
- 10.Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu islands. Gut. 2021;70:243–250. doi: 10.1136/gutjnl-2020-322200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–419. doi: 10.1111/j.1523-5378.2011.00889.x. [DOI] [PubMed] [Google Scholar]
- 12.Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7:e015855. doi: 10.1136/bmjopen-2017-015855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wagner S, Varrentrapp M, Haruma K, et al. The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. Z Gastroenterol. 1991;29:595–598. [PubMed] [Google Scholar]
- 14.Lee DH, Park HJ, Song SY, et al. Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Yonsei Med J. 1996;37:270–277. doi: 10.3349/ymj.1996.37.4.270. [DOI] [PubMed] [Google Scholar]
- 15.Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter. 2007;12 Suppl 2:50–58. doi: 10.1111/j.1523-5378.2007.00576.x. [DOI] [PubMed] [Google Scholar]
- 16.Chey WD, Wong BC Practice Parameters Committee of the American College of Gastroenterology, author. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825. doi: 10.1111/j.1572-0241.2007.01393.x. [DOI] [PubMed] [Google Scholar]
- 17.Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600. doi: 10.1111/j.1440-1746.2009.05982.x. [DOI] [PubMed] [Google Scholar]
- 18.Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730. doi: 10.1111/apt.13325. [DOI] [PubMed] [Google Scholar]
- 19.Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106–114. doi: 10.1111/apt.14130. [DOI] [PubMed] [Google Scholar]
- 20.Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50:751–759. doi: 10.1111/apt.15438. [DOI] [PubMed] [Google Scholar]
- 21.Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:864–872. doi: 10.1111/apt.15185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Kim SH, Cho KB, Chun HJ, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021;54:402–411. doi: 10.1111/apt.16477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Jung HK, Kang SJ, Lee YC, et al. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021;15:168–195. doi: 10.5009/gnl20288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97. doi: 10.1055/s-0028-1098086. [DOI] [Google Scholar]
- 25.Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278. doi: 10.1111/j.1523-5378.2007.00518.x. [DOI] [PubMed] [Google Scholar]
- 26.Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446. doi: 10.1136/gutjnl-2015-311304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.DeVault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol. 2009;6:524–532. doi: 10.1038/nrgastro.2009.125. [DOI] [PubMed] [Google Scholar]
- 28.Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12:317–323. doi: 10.1111/j.1523-5378.2007.00508.x. [DOI] [PubMed] [Google Scholar]
- 29.Mizuno H, Nishino M, Yamada K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 48-week maintenance therapy of patients with healed reflux esophagitis. Digestion. 2020;101:411–421. doi: 10.1159/000500399. [DOI] [PubMed] [Google Scholar]
- 30.Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy of seven-day potassium-competitive acid blocker-based first-line Helicobacter pylori eradication therapy administered with bismuth. Yonsei Med J. 2021;62:708–716. doi: 10.3349/ymj.2021.62.8.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Choi YJ, Lee YC, Kim JM, et al. Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial. Gut Liver. 2022;16:535–546. doi: 10.5009/gnl220055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Horikawa C, Kodama S, Fujihara K, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81–87. doi: 10.1016/j.diabres.2014.07.009. [DOI] [PubMed] [Google Scholar]
- 33.Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477–490. doi: 10.2165/00003088-199120060-00004. [DOI] [PubMed] [Google Scholar]
- 34.Nam SJ, Park SC, Lee SH, et al. Helicobacter pylori eradication in patients with type 2 diabetes mellitus: multicenter prospective observational study. SAGE Open Med. 2019;7:2050312119832093. doi: 10.1177/2050312119832093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Groop LC, Luzi L, DeFronzo RA, Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet. 1989;2:129–130. doi: 10.1016/S0140-6736(89)90184-0. [DOI] [PubMed] [Google Scholar]
- 36.Kong MF, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabet Med. 1996;13:112–119. doi: 10.1002/(SICI)1096-9136(199602)13:2<112::AID-DIA37>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
- 37.Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15:256–260. doi: 10.2337/diacare.15.2.256. [DOI] [PubMed] [Google Scholar]
- 38.Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13 Suppl 3:27–36. doi: 10.1046/j.1365-2036.1999.00022.x. [DOI] [PubMed] [Google Scholar]
- 39.Yoon DY, Lee S, Jang IJ, et al. Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation. Pharmaceutics. 2021;13:1489. doi: 10.3390/pharmaceutics13091489.8aa6e5a4b6eb431b92e05edbac01cd09 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.